From peanuts to fish oil

While we’re on the subject of controversial FDA advisory panels, Amarin now has a firm date — Nov. 14 — for its own inquisition...er...I mean review of its fish oil-derived heart drug Vascepa. You’ll recall Amarin was telling investors as late as early August that an FDA advisory panel for Vascepa was unlikely. Then, FDA apparently changed its mind, causing much head-scratching and stock (Amarin’s) selling. 

FDA should really think about selling tickets to this one.